Sicel nets FDA approval for implantable dosimeter
Sicel Technologies has received clearance from the FDA to begin marketing DVS-HFT, the next-generation of its original DVS (Dose Verification System) wireless implantable dosimeter for use in treating breast and prostate cancer patients undergoing external beam radiation therapy.
The DVS-HFT dosimeter is calibrated for use with radiation therapy protocols that give patients higher single doses of radiation over a shorter period of time compared with conventional radiation therapy, according to Morrisville, N.C.-based company.
Sicel said that recent changes by the Centers for Medicaid & Medicare Services (CMS) in the 2009 Hospital Outpatient reimbursement policy for Medicare patients will make DVS accessible to more patients undergoing radiation therapy treatment in hospital outpatient facilities. The change, effective Jan. 1, increased reimbursement to facilities implanting the sensors.
The DVS-HFT dosimeter is calibrated for use with radiation therapy protocols that give patients higher single doses of radiation over a shorter period of time compared with conventional radiation therapy, according to Morrisville, N.C.-based company.
Sicel said that recent changes by the Centers for Medicaid & Medicare Services (CMS) in the 2009 Hospital Outpatient reimbursement policy for Medicare patients will make DVS accessible to more patients undergoing radiation therapy treatment in hospital outpatient facilities. The change, effective Jan. 1, increased reimbursement to facilities implanting the sensors.